Oncology

Therapeutics, diagnostics and evidence shaping cancer care.

AML Trial Tests Mitoxantrone Liposome, Cladribine and Sotorasib

A phase 2 single-arm trial will test mitoxantrone liposome plus cladribine and sotorasib in relapsed or refractory AML, with ORR as the primary endpoint.

By Dr. Revathy Mohan V.R., MBBS · Oct 22, 2026 · 5 min read

Oncology·ScienceDaily

Ultra-Processed Foods Not Linked to Overall Colorectal Cancer Risk

In a 460,000-person cohort, total ultra-processed food intake was not tied to colorectal cancer, but food type within…

Oct 22, 2026

Oncology·JCI

NKG2C+ CD8 TKLR cells improve antitumor control and reduce CRS in mice

Engineered NKG2C+ CD8 TKLR cells controlled tumors longer and with less CRS than conventional CAR-T cells in mouse…

Oct 22, 2026

Oncology·ACC-PRO

Pancreatic Cancer Models Aim to Improve Individualized Drug Response Prediction

A review examines patient-derived xenografts, organoids, slice cultures, and chip-based models for predicting drug response in pancreatic cancer.

Oct 21, 2026

Oncology·Fierce HC

Cencora to buy majority stake in American Oncology Network for $2.4B

Cencora will acquire a majority stake in American Oncology Network, expanding its community oncology MSO reach across 21…

Oct 21, 2026

Oncology·Sci Transl Med

Somatic Mutation Shapes the Mutational Landscape of Normal Epithelia

Somatic mutations accumulate across epithelial tissues, but clonal competition, niche control, and exposures determine which mutant cells persist…

Oct 21, 2026

Oncology·Cancer Disc

Breast Cancer-Protective Variant Acts as cis-eQTL in HER2-Enriched Tumors

A protective 6q25 variant common in Indigenous American ancestry regulates ARMT1, RMND1, and CCDC170 in HER2-enriched breast tumors.

Oct 21, 2026

Oncology·Cancer Disc

Axitinib plus nivolumab tested first-line in advanced mucosal melanoma

A phase II study examined first-line axitinib plus nivolumab in advanced mucosal melanoma, a rare subtype with major…

Oct 21, 2026

Oncology·JCO

Cancer Immunotherapy Linked to Distinct Venous Thromboembolism Risk

A narrative review examines venous thromboembolism in cancer immunotherapy, including ICIs and CAR T therapy, and the limits…

Oct 21, 2026

Oncology·JCO

APR-1051 WEE1 Inhibitor Enters First-in-Human Phase 1 Testing

Early phase 1 testing of APR-1051, a WEE1 inhibitor, opened in patients with advanced solid tumors, marking first-in-human…

Oct 21, 2026

Oncology

Therapeutics, diagnostics and evidence shaping cancer care.

In Brief The 5-minute rounds

New hypertension guideline lowers the treatment threshold to 130/80 mm Hg.
Phase 3 GLP-1 trial reports a 20% cut in major adverse cardiac events.
FDA clears a next-generation CAR-T therapy for relapsed lymphoma.
Meta-analysis links early mobilisation to shorter ICU length of stay.
Rapid guidance broadens empiric antibiotics for suspected sepsis.